Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Purchases $32,850.00 in Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel purchased 2,500 shares of the business’s stock in a transaction on Thursday, July 23rd. The shares were purchased at an average price of $13.14 per share, with a total value of $32,850.00. Following the completion of the purchase, the chief executive officer owned 5,606,602 shares in the company, valued at approximately $73,670,750.28. This trade represents a 0.04% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Snehal Patel also recently made the following trade(s):

• On Wednesday, July 29th, Snehal Patel acquired 700 shares of Greenwich LifeSciences stock. The stock was acquired at an average price of $13.10 per share, for a total transaction of $9,170.00.
• On Monday, July 27th, Snehal Patel acquired 1,500 shares of Greenwich LifeSciences stock. The stock was acquired at an average cost of $13.62 per share, for a total transaction of $20,430.00.
• On Friday, July 24th, Snehal Patel acquired 1,100 shares of Greenwich LifeSciences stock. The stock was acquired at an average cost of $12.88 per share, for a total transaction of $14,168.00.

Greenwich LifeSciences Trading Up 9.5%

Shares of GLSI stock opened at $14.02 on Friday. Greenwich LifeSciences, Inc. has a 12 month low of $7.78 and a 12 month high of $34.10. The stock has a market cap of $205.79 million, a P/E ratio of -8.93 and a beta of 1.40. The company has a 50 day simple moving average of $21.07 and a two-hundred day simple moving average of $24.12.

Hedge Funds Weigh In On Greenwich LifeSciences

Several large investors have recently added to or reduced their stakes in the company. Marshall Wace LLP purchased a new stake in shares of Greenwich LifeSciences in the second quarter worth $509,000. Bank of New York Mellon Corp raised its position in shares of Greenwich LifeSciences by 235.5% during the 1st quarter. Bank of New York Mellon Corp now owns 46,523 shares of the company’s stock valued at $1,117,000 after purchasing an additional 32,657 shares during the period. Virtu Financial LLC purchased a new position in shares of Greenwich LifeSciences during the 4th quarter valued at $605,000. Man Group plc bought a new position in Greenwich LifeSciences in the 4th quarter worth $590,000. Finally, Sei Investments Co. bought a new position in Greenwich LifeSciences in the 1st quarter worth $627,000. Hedge funds and other institutional investors own 4.16% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on GLSI. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Greenwich LifeSciences in a report on Friday, May 15th. Wall Street Zen lowered Greenwich LifeSciences from a “hold” rating to a “sell” rating in a report on Saturday, June 6th. Finally, HC Wainwright upped their price target on Greenwich LifeSciences from $50.00 to $69.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $57.00.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.